India and the Pandemic Agreement: Equity, Technology Transfer and Pathogen Sharing
Revise the static topic: UPSC Social Justice notes · UPSC Science & Technology notes
In short: According to the supplied editorial, India’s intervention at the September 2026 UN High-Level Meeting linked pandemic cooperation with equitable access to medical products and respect for national sovereignty. The WHO Pandemic Agreement was adopted in 2025, but negotiations on its Pathogen Access and Benefit-Sharing annex remain unfinished, delaying its opening for ratification. India’s central challenge is to turn its pharmaceutical capacity and diplomatic influence into reliable access to vaccines, therapeutics and technology for itself and the Global South.
Why in news
The supplied editorial examines India’s position on the Political Declaration on Pandemic Prevention, Preparedness and Response at the September 2026 UN High-Level Meeting. It highlights the unresolved pathogen benefit-sharing negotiations as a critical test of equitable global pandemic governance.
124
Member-states supporting adoption, as reported
11
Abstentions at adoption
2025
Pandemic Agreement adopted
Background
Pandemics expose the mismatch between nationally organised health systems and infectious threats that cross borders. The World Health Organization provides a forum for international health cooperation, while the International Health Regulations address the prevention and management of cross-border public-health risks. The Pandemic Agreement seeks to strengthen cooperation across prevention, preparedness and response, including access to medical products and manufacturing capacity. COVID-19 demonstrated that scientific breakthroughs and aggregate production do not automatically ensure timely or affordable access: financing, intellectual property, supply chains and allocation decisions also shape outcomes.
What has been agreed, and what remains unresolved?
The source reports that the Pandemic Agreement was adopted in 2025 with support from 124 member-states, including India, while 11 abstained and none voted against it. Its negotiations exposed disagreements over national sovereignty, financing, technology transfer and the responsibilities of private manufacturers.
According to the editorial, the Agreement is not yet open for ratification because negotiations on the Pathogen Access and Benefit-Sharing system remain ongoing. Adoption is therefore an important diplomatic milestone, not proof that all proposed commitments are already legally operational.
The UN Political Declaration and the WHO Pandemic Agreement must also be distinguished. A political declaration expresses commitments and priorities; it is not equivalent to ratification of a treaty or implementation of its obligations.
- The unresolved annex concerns the relationship between access to pathogens and access to benefits arising from their use.
- The practical test is whether cooperation delivers medical products during a crisis, rather than only after urgent demand has subsided.
- The editorial records India’s support for international coordination shaped by national circumstances.
Infographic
Fair access
Allocate vaccines and therapeutics by need, not purchasing power alone.
Reciprocal sharing
Connect pathogen access with predictable and transparent benefits.
Technology capability
Combine licensing with know-how, skills and quality systems.
Funded preparedness
Support One Health, laboratories and workforce capacity.
Cooperative sovereignty
Preserve national ownership while enabling collective action.
Domestic credibility
Align India’s internal resilience and equity with its global demands.
AI-assisted infographic by Pragnya IAS Academy, based on the cited sources.
Pathogen access must be matched by equitable benefit-sharing
Pathogen sharing supports research, risk assessment and the development of vaccines, diagnostics and therapeutics. However, countries supplying biological material may still struggle to obtain the resulting products if purchasing power and exclusive commercial arrangements determine access.
The proposed PABS system seeks to address this imbalance by connecting pathogen access with benefit-sharing. For low- and middle-income countries, its credibility will depend on whether the final rules secure timely, affordable and predictable access to pandemic-related products.
The source does not establish final allocation quotas, pricing rules or enforcement arrangements. These should be treated as questions for negotiation, not as settled provisions.
- Allocation should reflect public-health need rather than purchasing power alone.
- Predictable benefits can strengthen countries’ incentives to participate in pathogen-sharing arrangements.
- Transparent manufacturer commitments would be more reliable than dependence on discretionary donations.
- A workable mechanism must preserve rapid scientific collaboration while addressing inequitable commercial outcomes.
Why India needs technology access despite its manufacturing strength
India is a major pharmaceutical and vaccine producer, but production capacity is not synonymous with technological autonomy. The editorial highlights intellectual-property ownership by global pharmaceutical firms in vaccine manufacturing arrangements, import dependence for active pharmaceutical ingredients, and the need for advanced technology in medical devices and high-grade protective equipment.
Technology transfer involves more than permission to use a patent. It can require manufacturing know-how, trained personnel, quality-control systems, access to inputs and regulatory support. Licensing without these complementary capabilities may not translate into rapid production.
India therefore occupies a dual position: it seeks access to advanced technologies while possessing capabilities that can support other developing countries. Its strongest negotiating position combines domestic supply-chain resilience with credible South-South cooperation.
- Diversified production can reduce dependence on a narrow group of suppliers.
- Domestic manufacturing must be accompanied by affordable procurement and equitable distribution.
- Partnerships should build durable capabilities rather than create only short-term supply contracts.
Sovereignty, financing and India’s bridge-building role
The editorial identifies sovereignty as a concern across income groups, although the underlying interests differ. African countries resisted monitoring commitments at the human-animal-environment interface without significant funding, while countries in the Global North resisted binding technology-transfer targets.
This is fundamentally a question of matching responsibilities with resources. One Health surveillance requires laboratories, trained workers, interdepartmental coordination and sustained finance. Imposing obligations without enabling capacity risks formal compliance without meaningful preparedness.
India can bridge these divides by developing practical partnerships in surveillance, workforce strengthening, laboratory networks and digital health. Its international credibility will also depend on whether domestic rules governing biological-material access and benefit distribution reflect the equity principles it advocates abroad.
- Sovereignty should enable nationally appropriate implementation without becoming a blanket justification for non-cooperation.
- Financing and technical assistance should accompany additional preparedness responsibilities.
- India’s digital health experience can support cooperation when paired with privacy safeguards, interoperability and local ownership.
- Existing multilateral health platforms can help sustain political attention beyond emergency periods.
| Issue | Governance problem | India’s policy interest |
|---|---|---|
| Pathogen sharing | Scientific inputs may circulate faster than the benefits derived from them. | Secure predictable benefit-sharing while maintaining timely research cooperation. |
| Vaccine and therapeutic access | Commercial purchasing power may outweigh public-health need. | Support transparent, affordable and needs-based allocation. |
| Technology transfer | Manufacturing capacity may lack licences, know-how or critical inputs. | Pursue capability-building partnerships and diversified production. |
| One Health | Surveillance responsibilities can exceed countries’ financial and technical capacity. | Link commitments to sustainable financing and implementation support. |
| National sovereignty | Domestic policy autonomy may conflict with expectations of collective action. | Preserve national ownership while accepting credible cooperation mechanisms. |
- 1. Countries detect health threats and share relevant pathogen material through agreed arrangements.
- 2. Researchers and manufacturers use the material to develop medical countermeasures.
- 3. Agreed benefit-sharing responsibilities connect access to scientific inputs with access to resulting benefits.
- 4. Transparent allocation arrangements prioritise public-health need and affordability.
- 5. National health systems procure, distribute and administer products effectively.
- 6. Monitoring and accountability identify access gaps and guide corrective action.
2023
The Global Initiative for Digital Health was launched during India’s G20 presidency, as noted in the editorial.
2025
The Pandemic Agreement was adopted with India’s support; the source reports 124 supporting member-states and 11 abstentions.
September 2026
According to the editorial, India addressed the UN High-Level Meeting on pandemic prevention, preparedness and response, emphasising equity, cooperation and sovereignty.
Status reported in the supplied editorial
PABS annex negotiations remain ongoing, and the Agreement is not yet open for ratification.
Significance, challenges & way forward
Significance
- An equitable agreement can make access to pandemic products a predictable component of preparedness rather than an uncertain act of charity.
- Credible benefit-sharing can build trust between pathogen-providing countries, researchers and manufacturers.
- Technology partnerships can help India move from manufacturing scale towards greater technological resilience.
- India can connect the interests of major producers with those of countries facing limited purchasing power and weak health systems.
- Investment in surveillance, laboratories and health workers can strengthen routine health services as well as emergency response.
Challenges
- The unfinished PABS annex leaves the central exchange between pathogen access and benefit-sharing unresolved.
- Resistance to binding technology-transfer commitments can limit the practical value of manufacturing cooperation.
- Unfunded preparedness obligations may impose disproportionate burdens on countries with fragile health systems.
- Intellectual-property constraints, limited know-how and dependence on imported inputs can slow production expansion.
- Sovereignty concerns can obstruct coordination if countries interpret collective responsibilities as unacceptable external control.
- Domestic procurement, logistics and delivery weaknesses can prevent internationally allocated supplies from reaching vulnerable populations.
Way forward
- India should advocate clear PABS responsibilities, transparent benefit-allocation criteria and workable accountability arrangements.
- Preparedness commitments should be linked to predictable finance, technical assistance and differentiated implementation support.
- Technology partnerships should combine licensing with know-how, workforce training, quality assurance and regulatory cooperation.
- India should strengthen critical-input supply chains while maintaining reliable international partnerships.
- Domestic rules on biological-material access and benefit-sharing should be transparent, equitable and supportive of timely research.
- South-South cooperation should build locally owned surveillance, manufacturing and health-delivery capabilities.
- India should use multilateral health platforms to sustain preparedness investment and review implementation between emergencies.
Key terms
- Pandemic Prevention, Preparedness and Response
- The continuum of measures to reduce outbreak risks, build readiness and manage health emergencies.
- Pathogen Access and Benefit-Sharing
- A proposed system linking access to pathogens with fair sharing of benefits arising from their use.
- One Health
- An integrated approach recognising the interdependence of human, animal and ecosystem health.
- Technology transfer
- The sharing of knowledge, skills, processes and relevant rights needed to develop or manufacture a product.
- Active Pharmaceutical Ingredient
- The component of a medicine responsible for its intended pharmacological effect.
- Ratification
- An international act through which a state establishes its consent to be bound by a treaty.
- South-South cooperation
- Cooperation among developing countries through exchanges of knowledge, resources, technology and expertise.
Link with static syllabus
Prelims practice MCQs
Q1. With reference to the Pandemic Agreement as described in the supplied editorial, consider the following statements: 1. India supported its adoption in 2025. 2. Negotiations on the PABS annex have been completed. 3. Adoption by itself means that all proposed commitments are already legally operational. Which of the statements given above is/are correct?
Q2. Which of the following best describes the intended purpose of the Pathogen Access and Benefit-Sharing system?
Q3. Consider the following statements about One Health: 1. It recognises links between human, animal and ecosystem health. 2. Its implementation can require coordination across health, veterinary and environmental institutions. 3. It is confined to hospital-based treatment of infectious diseases. Which of the statements given above are correct?
Q4. With reference to pharmaceutical technology transfer, consider the following statements: 1. Permission to use a patent necessarily provides all the know-how needed for commercial production. 2. Workforce training and quality-control systems can be important components of effective technology transfer. 3. Large manufacturing capacity can coexist with dependence on imported active pharmaceutical ingredients. Which of the statements given above are correct?
Mains practice questions
GS 2 · 15 marks · 250 words
India’s pharmaceutical strength does not eliminate its dependence on an equitable global pandemic regime. Discuss with reference to pathogen benefit-sharing, technology transfer and national sovereignty.
Frequently asked questions
Is the Pandemic Agreement already fully operational?
Not according to the supplied editorial: it has been adopted, but is not yet open for ratification because PABS annex negotiations remain unfinished. Adoption should not be equated with full legal operation.
Why does India need equitable vaccine access if it is a major producer?
Production capacity can coexist with dependence on technology, intellectual-property permissions and imported inputs. Equitable allocation and resilient domestic delivery are also necessary to turn available production into timely access.
How is technology transfer different from vaccine donation?
Donation supplies finished products, whereas technology transfer helps recipients acquire the capabilities needed to produce them. Durable transfer may require licences, know-how, training and quality-control support.
Does sovereignty necessarily conflict with pandemic cooperation?
No. Cooperation can preserve national ownership while establishing agreed responsibilities, provided these are clear, feasible and supported by appropriate resources.
Sources
Analysis prepared by the Pragnya IAS Academy current-affairs desk with AI assistance from the cited reports. Verify figures with the original sources.
Turn current affairs into marks
Join Pragnya IAS Academy's mentorship for daily answer-writing evaluation on stories like this.